This study tested the hypothesis that nitric oxide (NO) and atrial natriuretic peptide (ANP) can attenuate the effects of adrenergic agonists on the growth of cardiac myocytes and fibroblasts. In ventricular cells cultured from neonatal rat heart, ANP and the NO donor Snitroso-N-acetyl-D,L-penicillamine (SNAP) caused concentration-dependent decreases in the norepinephrine (NE)-stimulated incorporation of [3H]leucine in myocytes and [3H]thymidine in fibroblasts. In myocytes, the NO synthase inhibitor NG-monomethyl-Larginine potentiated NE-stimulated [3H]leucine incorporation. In both cell types, ANP and SNAP increased intracellular cGMP levels, and their growth-suppressing effects were mimicked by the cGMP analogue 8-bromo-cGMP. Furthermore, in myocytes, 8-bromocGMP attenuated the alpha1-adrenergic receptor-stimulated increases in c-fos. Likewise, ANP and 8-bromo-cGMP attenuated the alpha1-adrenergic receptor-stimulated increase in prepro-ANP mRNA and the alpha1-adrenergic receptor-stimulated decrease in sarcoplasmic reticulum calcium ATPase mRNA. The L-type Ca2+ channel blockers verapamil and nifedipine inhibited NE-stimulated incorporation of [3H]leucine in myocytes and [3H]thymidine in fibroblasts, and these effects were not additive with those of ANP, SNAP, or 8-bromo-cGMP. In myocytes, the Ca2+ channel agonist BAY K8644 caused an increase in [3H]leucine incorporation which was inhibited by ANP. These findings indicate that NO and ANP can attenuate the effects of NE on the growth of cardiac myocytes and fibroblasts, most likely by a cGMP-mediated inhibition of NE-stimulated Ca2+ influx. 
Introduction
Norepinephrine (NE) 1 induces myocardial hypertrophy associated with increased protein synthesis by myocytes, the induction of a fetal gene program, and the development of interstitial fibrosis (1) (2) (3) (4) . In cultured cardiac myocytes, NE causes myocyte hypertrophy and fetal gene expression primarily via activation of ␣ 1 -adrenergic receptors (2) , whereas in cultured cardiac fibroblasts, the induction of DNA synthesis and proliferation by NE is mediated by ␤ -adrenergic receptors (5) . In both myocytes and fibroblasts, NE, acting via ␣ 1 -adrenergic or ␤ -adrenergic receptors, respectively, causes the expression of peptide growth factors that can exert autocrine or paracrine effects on growth and gene expression (4, 5) .
cGMP and substances that increase cellular cGMP, such as natriuretic peptides and nitric oxide (NO)-generating molecules, inhibit the stimulation of DNA synthesis by angiotensin, endothelin, and peptide growth factors in vascular smooth muscle cells, endothelial cells, mesangial cells, and cardiac fibroblasts (6-9, 10). There is no information about the effect of cGMP on protein synthesis in cardiac myocytes, or on the ability of cGMP-elevating substances to inhibit the growth-promoting effects of NE in either myocytes or fibroblasts from the heart. However, cardiac myocytes and fibroblasts have receptors for natriuretic peptides (10, 11) , the myocardium can produce nitric oxide (12, 13) , and a characteristic of the hypertrophic response is the induction of atrial natriuretic peptide (ANP) in cardiac myocytes (2, 14) . Taken together, these observations raise the possibility that natriuretic peptides and NO could attenuate the effects of NE on the growth and phenotype of the myocardium.
Therefore, the primary purpose of this study was to test the hypothesis that cGMP and the cGMP-generating substances NO and ANP inhibit the ability of NE to cause growth of cardiac myocytes and fibroblasts. Our second, related goal was to test the hypothesis that cGMP inhibits the effect of NE on myocyte gene expression. These hypotheses were examined in cultures of neonatal rat cardiac myocytes and fibroblasts by determining the ability of cGMP, ANP, the NO donor S -nitroso-N -acetyl-D , L -penicillamine (SNAP), and the NO synthase inhibitor N G -monomethyl-L -arginine (L-NMMA) to modulate NE-stimulated protein synthesis and gene expression in myocytes, and DNA synthesis in fibroblasts. Finally, since NE increases Ca 2 ϩ influx via L-type Ca 2 ϩ channels (15), and cGMP inhibits L-type Ca 2 ϩ channels in cardiac myocytes (16) (17) (18) , our third goal was to examine the possibility that the growth-inhibiting effects of cGMP are mediated via inhibition of Ca 2 ϩ influx.
Methods
Cultured neonatal rat cardiac myocytes and fibroblasts. Neonatal rat ventricular myocytes were isolated by a modification of the technique of Kasten (19) , as described previously (4) . Briefly, hearts were removed from 2-d-old neonatal rats anesthetized with ether and killed by decapitation. Ventricular tissues were digested with 0.1% trypsin (Worthington Biochemical Corp., Freehold, NJ) in HBSS (Ca 2 ϩ free; GIBCO BRL, Gaithersburg, MD) overnight at 4 Њ C. Ventricular cells were then recovered by repeated digestions of the tissue in 10 ml of 0.1% collagenase in HBSS. The supernatants collected from each digestion were centrifuged at 100 g for 3 min (4 Њ C). The pellets were resuspended in ice cold HBSS, pooled, and centrifuged at 100 g for 4 min (4 Њ C). Cells were resuspended in DME containing 7% heat-inactivated FBS and preplated twice on T80 flasks (Nunc, Inc., Naperville, IL) for 75 min to enrich for myocytes and decrease contamination by nonmuscle cells. The nonadherent myocytes were then plated at a density of 100-200 cells/mm 2 for [ 3 H]leucine incorporation (24-well plate; Costar Corp., Cambridge, MA) and mRNA studies (100-mm plate; Fisher Scientific Co., Pittsburgh, PA). After 24 h, the culture medium was changed to serum-free DME containing insulin (5 g/ml), transferrin (5 g/ml), and sodium selenite (5 ng/ml); all experiments were performed 24 h later.
Cultures of neonatal rat ventricular nonmyocytes, which have been shown to be predominantly fibroblasts (20) , were prepared as described previously by Sadoshima and Izumo (21) . Briefly, hearts obtained from neonatal rats were enzyme-digested as described above for myocytes. The adherent nonmyocyte fractions obtained during preplating on T80 flasks were grown in DME containing 7% FBS until confluent (5-7 d), and passaged with trypsin-EDTA (0.25%, 0.53 mM; GIBCO BRL). All experiments were performed on cells from the first or second passages which were placed in serumfree DME containing insulin (5 g/ml), transferrin (5 g/ml), and sodium selenite (5 ng/ml) for 24 h before the experiment. cGMP production. Myocytes and fibroblasts plated in 6-well plates (Costar Corp.) were pretreated with isobutylmethylxanthine (0.2 mM) for 15 min before the addition of ANP (100 nM) or SNAP (100 nM), and incubated at 37 Њ C for an additional 30 min. The reaction was stopped by the addition of 0.1 M HCl, the plates were placed on ice for 30 min, and the supernatant was collected and titrated to pH 7.4 with 2.5 M sodium acetate (pH 5.8) and 5 M NaOH. cGMP levels were quantitated with a standard RIA kit (Biomedical Technologies, Inc., Stoughton, MA). NaOH (0.2 M) was subsequently added to the plates for 30 min, the cells were scraped, and the protein content was measured by the Bradford technique (Bio-Rad Laboratories, Hercules, CA) with BSA as a standard.
Assessment of mRNA levels. Myocytes were plated at a density of 200 cells/mm 2 in P100 plates (Falcon Labware, Cockeysville, MD). Myocyte mRNA levels were measured as described previously (4) . Briefly, myocytes were treated with ANP (100 nM) or 8-bromocGMP (1 mM) for 5-10 min before the addition of 1 M NE (in the presence of 10 M propranolol) and harvested 30 min or 24 h later to examine c-fos and prepro-ANP mRNA levels, respectively. Myocytes were resuspended in denaturing solution (4M guanidium thiocyanate, 25 mM sodium citrate, 0.5% laurylsarcosine, 0.1 M mercaptoethanol, pH 7). RNA was denatured with formaldehyde and formamide, and separated by size electrophoresis on a 1.3% agarose/4% formaldehyde gel (15 g total RNA/lane). RNA was transferred to nylon membranes (Genescreen Plus; DuPont-NEN) by vacuum blotting (model 785; Bio-Rad Laboratories) and ultraviolet cross-linked (Stratalinker 1800; Stratagene Inc., La Jolla, CA).
Full-length cDNAs of rat prepro-ANP (courtesy of Dr. C. Seidman, Harvard Medical School) and mouse c-fos (courtesy of Dr. M. Greenberg, Harvard Medical School) were labeled with [
32 P]dCTP (DuPont-NEN) to a specific activity of 1-2 ϫ 10 6 cpm/ng cDNA by the random hexamer priming method, and hybridized to nylon blots for 18-24 h at 42 Њ C. Blots were washed twice (15 min, room temperature) with 300 mM NaCl/30 mM trisodium citrate (pH 7) and 0.1% SDS, and twice (15 min, 50-55 Њ C) with 30 mM NaCl/3 mM trisodium citrate (pH 7) and 0.1% SDS. Blots were exposed to XAR film (Eastman Kodak Co., Rochester, NY) with an intensifying screen at Ϫ 70 Њ C, and films were scanned with a laser densitometer (UltraScan 2202; LKB, Uppsala, Sweden). The sizes of the hybridized messages were estimated using 18S and 28S rRNA bands as standards. All blots were reprobed with a [ 32 P]ATP-labeled oligonucleotide complimentary to 18S rRNA (23) , and all levels of mRNA reported in this manuscript are normalized to the level of 18S rRNA to correct for potential variations in the amount of RNA loaded or transferred.
Results

ANP and SNAP attenuate NE-stimulated protein synthesis in myocytes.
The addition of NE (1 M) to cultured myocytes for 24 h caused a 60 Ϯ 9% ( P Ͻ 0.001; n ϭ 7) increase in adrenergic receptors (1, 2) . The addition of ANP for 24 h had no effect on basal [ 3 H]leucine incorporation, but caused a concentration-dependent inhibition of the NE-stimulated increase (Fig. 2 A ) . At the highest concentration tested (100 nM), ANP attenuated the NE-mediated increase in [ 3 H]leucine incorporation by 53 Ϯ 7% ( P ϭ 0.001; n ϭ 15) (Fig. 1) .
Similarly, addition of the NO-donor SNAP to myocytes for 24 h had no effect on basal [ (Fig. 2 B) . At the highest concentration tested (100 M), SNAP attenuated the NE-stimulated increase in [ 3 H]leucine incorporation by 53Ϯ6% (P ϭ 0.001; n ϭ 6) (Fig. 1) .
NO synthase inhibition potentiates NE-stimulated protein synthesis in myocytes. The addition of L-NMMA (1 mM) for 24 h had no effect on basal [ 3 H]leucine incorporation in myocytes (2Ϯ8% increase vs. basal), but potentiated NE-stimulated [ 3 H]leucine incorporation by 44Ϯ5% (NE alone, ϩ76Ϯ 8% vs. basal; NE plus L-NMMA, ϩ109Ϯ13% vs. basal; n ϭ 6; P Ͻ 0.01) (Fig. 3) .
Role of cGMP in mediating the inhibitory effects of ANP and SNAP. In myocytes, the addition of ANP (100 nM) or SNAP (100 M) for 30 min increased the cellular content of cGMP by two-to threefold (basal, 25Ϯ3 pmol/mg protein; ANP, 61Ϯ3 pmol/mg protein; SNAP, 81Ϯ12 pmol/mg protein; n ϭ 2 for each), confirming that each is capable of stimulating cGMP production in neonatal cardiac myocytes. To determine whether cGMP can mimic the effects of ANP and SNAP, the cGMP analog 8-bromo-cGMP (1 mM) was added to cultures 15 min before NE. 8-Bromo-cGMP inhibited NE-stimulated [ 3 H]leucine incorporation by 57Ϯ10% (P ϭ 0.002; n ϭ 10) (Fig. 1) . In a separate set of experiments, NE-stimulated [ 3 H]leucine incorporation was inhibited 48Ϯ9% by 8-bromocGMP, 59Ϯ8% by ANP, and 54Ϯ9 by the combination of ANP and cGMP (P ϭ NS; n ϭ 4). Thus, the inhibitory effects of 8-bromo-cGMP and ANP were not additive.
The addition of 8-bromo-cGMP for 4 h followed by a washout immediately before the addition of NE for 24 h did not attenuate the NE-stimulated increase in [ (Fig. 4 A) . The addition of 8-bromo-cGMP (1 mM) for 30 min had no effect on the basal level of c-fos mRNA. However, the addition of 8-bromo-cGMP 15 min before the addition of NE attenuated the NE-stimulated increase in c-fos mRNA levels by 72Ϯ10% (P ϭ 0.002; n ϭ 3) (Fig. 4 B) .
cGMP modulates the effects of NE on the levels of prepro-ANP and sarcoplasmic reticulum calcium ATPase (SERCA2) mRNA. The addition of NE (1 M plus 10 M propranolol) to myocytes for 24 h increased the level of prepro-ANP mRNA 11Ϯ3-fold (n ϭ 10) (Fig. 5, A and B) . The concurrent addition of 8-bromo-cGMP (1 mM) attenuated the NE-stimulated increase by 47Ϯ13% (P Ͻ 0.004 vs. NE-stimulated; n ϭ 9) compared with cells not exposed to 8-bromo-cGMP (Fig. 5  B) . Likewise, the concurrent addition of ANP (100 nM) attenuated the NE-stimulated increase in prepro-ANP mRNA by 42Ϯ4% compared with myocytes not exposed to ANP (P ϭ 0.002 vs. NE-stimulated; n ϭ 3).
The addition of NE (1 M plus 10 M propranolol) to myocytes for 24 h decreased the level of SERCA2 mRNA by 49Ϯ6% (n ϭ 6). The concurrent addition of 8-bromo-cGMP (1 mM) (Fig. 5 B) or ANP (100 nM) for 24 h attenuated this effect by 60Ϯ17% (P Ͻ 0.01; n ϭ 6) and 60% (n ϭ 2), respectively. (Fig. 6 ). The addition of propranolol (10 M) inhibited the NE-stimulated increase by 80Ϯ5% (12Ϯ3% increase vs. basal; P Ͻ 0.001; n ϭ 8), confirming that under these conditions, NE-stimulated DNA synthesis is mediated predominantly by ␤-adrenergic receptors (5).
ANP, NO, and cGMP inhibit NE-stimulated [
The addition of ANP (100 nM) had no effect on basal [ (Fig.  2 A) . At the highest concentration tested, ANP (100 nM) attenuated NE-stimulated [ 3 H]thymidine incorporation by 70Ϯ 8% (P Ͻ 0.001; n ϭ 11) (Fig. 6 ). The addition of SNAP for 24 h caused a concentration-dependent decrease in basal [ (Fig. 2 B) . At the highest concentration tested, SNAP (100 M) attenuated the NE-stimulated increase in [ 3 H]thymidine incorporation by 80Ϯ11% (P ϭ 0.001 vs. SNAP alone; n ϭ 4) (Fig. 6) .
Role of cGMP in mediating the effects of ANP and NO in fibroblasts. ANP (100 nM) and SNAP (100 M) increased cellular cGMP content in fibroblasts by ‫ف‬ 5-and 50-fold, respectively (basal, 51Ϯ9 pmol/mg protein/30 min; ANP, 240Ϯ6 pmol/mg protein/30 min; SNAP, 2,700Ϯ150 pmol/mg protein/30 min; n ϭ 2 each). The addition of the cGMP analogue 8-bromo-cGMP (1 mM) alone for 24 h decreased basal (Fig. 7 A) and 63Ϯ4% (P Ͻ 0.01; n ϭ 3), respectively. The inhibition of NE-stimulated [ 3 H]leucine incorporation by verapamil was not additive with that caused by ANP (100 nM) (Fig. 7 B) , SNAP (100 M), or 8-bromo-cGMP (1 mM) (data not shown).
In fibroblasts, the addition of verapamil for 24 h decreased basal [ 
Discussion
The major new finding of this study is that ANP and NO exerted an antiadrenergic action by inhibiting the growth-promoting effects of NE in both cardiac myocytes and fibroblasts. NE stimulated protein synthesis in cardiac myocytes via activation of ␣ 1 -adrenergic receptors and stimulated DNA synthesis in cardiac fibroblasts via activation of ␤-adrenergic receptors. Both effects of NE were attenuated by ANP and NO. Conversely, inhibition of endogenous NO synthesis potentiated the magnitude of NE-stimulated protein synthesis. ANP and NO were coupled to the generation of cGMP in cardiac myocytes and fibroblasts, and cGMP mimicked the effects of ANP and NO in both cell types, suggesting that the growth-inhibiting effects of ANP and NO are mediated, at least in part, by cGMP. Consistent with these observations, we found that cGMP inhibited the reciprocal NE-stimulated changes in prepro-ANP (increase) and SERCA2 (decrease) mRNA levels that are characteristic of hypertrophied myocardium (24, 25) . cGMP also attenuated the NE-stimulated induction of c-fos mRNA, indicating that its growth-inhibiting action may be mediated, at least in part, by inhibition of one or more early response genes.
There is precedent for a growth-inhibiting effect of cGMP and cGMP-generating compounds in vascular smooth muscle cells and cardiac fibroblasts. In vascular smooth muscle cells, ANP, NO, and cGMP can inhibit serum-, epidermal growth factor-, or angiotensin-stimulated DNA synthesis and proliferation (6, 8, 10) . NO has also been shown to inhibit serum-stimulated protein and collagen synthesis in vascular smooth muscle cells (26) . In fibroblasts from neonatal rat heart, Long et al. (5) have shown that adrenergic agonists induce DNA synthesis via ␤-rather than ␣ 1 -adrenergic receptors, which are not expressed in this cell type (27) . Our data indicate that in cardiac fibroblasts, ␤-adrenergic receptor-stimulated DNA synthesis is inhibited by ANP, NO, and cGMP. Recently, Cao and Gardner (9) have shown that ANP, NO, and cGMP inhibit peptide growth factor-, angiotensin-, and endothelin-stimulated DNA synthesis in cardiac fibroblasts. Therefore, our observations in cardiac fibroblasts extend the growth-inhibiting effect of cGMP-generating compounds to the ␤-adrenergic signaling pathway, and together with the findings in cardiac myocytes, provide the first evidence that cGMP-generating compounds exert an antiadrenergic effect on the hypertrophic actions of NE in the myocardium.
These data add to the known physiologic actions of ANP, NO, and cGMP in the myocardium. ANP acts via three receptor subtypes, termed A, B, and C, all of which have been identified in adult rat myocardium (28) , and cardiac myocytes and fibroblasts isolated from adult rat heart (11). In neonatal rat cardiac myocytes, ANP inhibits both the amplitude of spontaneous contractions and Ca 2ϩ influx (29) . Likewise, NO, which couples to the generation of cGMP, can exert a direct negative inotropic effect on the myocardium (30) . Further, it has been shown that cGMP and NO can inhibit the contractile responses to both ␣ 1 -and ␤-adrenergic receptor stimulation (13, 31) . It has been suggested that the negative inotropic effects of cGMP, ANP, and NO are due to inhibition of Ca 2ϩ influx via the L-type Ca 2ϩ channel (16, 17) . In contrast to amphibian cells, in which this effect is due to activation of a phosphodiesterase with a resultant decrease in cAMP, in mammalian cells, the effect of cGMP to inhibit Ca 2ϩ influx does not depend on changes in cAMP, but rather appears to reflect a direct effect on the channel (16) (17) (18) .
Our data suggest that the growth-inhibiting effects of cGMP, ANP, and NO in cardiac myocytes and fibroblasts were mediated in part by the inhibition of Ca 2ϩ influx. First, in myocytes, protein synthesis stimulated by the Ca 2ϩ channel agonist BAY K8644 was inhibited by ANP. Second, the growthinhibiting effects of ANP and NO were mimicked both qualitatively and quantitatively by the Ca 2ϩ channel antagonists verapamil and nifedipine. Finally, the effects of verapamil and nifedipine were not additive with those of ANP, NO, or cGMP in myocytes or fibroblasts.
The role of Ca 2ϩ influx in mediating the myocyte growth response to NE is not clearly established, in part due to the technical difficulty of dissociating direct effects of Ca 2ϩ from indirect effects due to cellular contraction (32) . However, in neonatal rat cardiac myocytes, NE causes cellular growth and induction of prepro-ANP mRNA primarily via activation of ␣ 1 -adrenergic receptors of the pharmacological A subtype (2), which are coupled to an increase in L-type Ca 2ϩ channel current in cardiac myocytes (15) . Likewise, it has been shown that Ca 2ϩ influx is essential for the ␣ 1 -adrenergic receptor-stimulated induction of prepro-ANP mRNA (14) . In cardiac fibroblasts, ␤-adrenergic receptor stimulation, presumably acting via cAMP, also increases the L-type Ca 2ϩ channel current (33). Booz et al. (34) observed that angiotensin-stimulated DNA synthesis is mediated, at least in part, via a Ca 2ϩ -dependent pathway in neonatal rat cardiac fibroblasts.
Since myocytes exhibit spontaneous contractions under the conditions of these experiments, we cannot determine whether the growth-inhibiting effects we observed were due to a direct decrease in intracellular Ca 2ϩ or an indirect effect of reduced contractions. However, since fibroblasts do not contract spontaneously under these conditions, we can conclude that in these cells, the growth-promoting effect of Ca 2ϩ influx is not related to contraction, and most likely reflects a direct biochemical action. We cannot exclude a role for non-cGMPmediated effects of ANP or NO. In cardiac fibroblasts, ANP inhibition of serum-stimulated DNA synthesis appears to be mediated not only by the A and B subtypes, but also by the C subtype (9), which is not coupled to cGMP, and there is evidence for an antimitogenic effect of the C subtype in rat aortic smooth muscle and glial cells (35, 36) .
Recently, Zheng et al. (37) observed that ATP inhibits hypertrophy stimulated by NE, basic fibroblast growth factor, and endothelin-1 in neonatal cardiac myocytes. It is noteworthy that the effects of ATP and cGMP on ␣ 1 -adrenergic receptor-stimulated hypertrophy differ in several ways. First, they exhibit markedly different temporal requirements. Whereas a transient preexposure to ATP inhibits the subsequent ability of ␣ 1 -adrenergic receptor stimulation to cause hypertrophy, cGMP must be present continuously with NE to exert its inhibitory action. Second, whereas ATP itself stimulates c-fos mRNA and does not inhibit the stimulation by NE, cGMP has no effect by itself and inhibits markedly the stimulation caused by NE. Third, cGMP but not ATP inhibits the ability of NE to downregulate the level of SERCA2 mRNA. These differences suggest that the two nucleotides inhibit ␣ 1 -adrenergic receptor-stimulated myocyte growth by distinct mechanisms.
In contrast to our findings, Harding et al. (38) found that phenylephrine-stimulated protein synthesis in neonatal rat cardiac myocytes was not inhibited by cGMP. Of note, we have found that the inhibitory effect of cGMP is absent in cells cultured at high density (1,000 cell/mm 2 ), suggesting that this discrepancy may reflect our use of low density (100-200 cells/ mm 2 ) cultures as opposed to the high density (1,000 cells/mm 2 ) cultures used by Harding et al. (38) . This thesis is supported by evidence that cell density can exert qualitative effects on the pathways that mediate NE-stimulated protein synthesis in neonatal rat cardiac myocytes (39).
The implications of these findings remain to be demonstrated. However, they raise the possibility that NO, ANP, and other cGMP-generating compounds could attenuate the effects of NE on the growth and phenotype of the myocardium. Such antiadrenergic actions might play an adaptive, counterregulatory role by acting in an autocrine or paracrine manner to limit the adverse effects (e.g., interstitial fibrosis and fetal gene induction) of increased sympathetic tone on the myocardium. This thesis is supported by a recent report from Wu et al. (40) that ANP stimulates apoptosis in neonatal rat cardiac myocytes and that this effect is abolished by norepinephrine, which by itself has no affect on apoptosis in this system. Although ANP expression is minimal or absent in normal ventricular myocardium, several hypertrophic stimuli induce natriuretic peptides (23) . Furthermore, expression of constitutive NO synthase (NOS3) and NO production are present in cardiac myocytes (13) , and cardiac NO production may be increased due to induction of inducible NO synthase (NOS2) in pathological states such as myocardial failure (41) . Our finding that inhibition of NO synthesis by L-NMMA potentiated NE-stimulated protein synthesis in myocytes suggests that basal levels of endogenous NO production could modulate myocyte growth. Consistent with this view, myocardial hypertrophy and fetal gene expression were attenuated by chronic administration of the NO precursor L-arginine in the spontaneously hypertensive rat (42) . Conversely, it is possible that excessive activation of ANP, NO, and other cGMP-generating pathways could be maladaptive by suppressing the requisite myocardial response to adrenergic or other hypertrophic stimuli. Understanding the physiologic and pathophysiologic effects of NO, natriuretic peptides, and other cGMP-generating compounds in the myocardium may allow the development of new strategies for modulating the growth and phenotype of the myocardium.
